---
title: Inebilizumab for Treatment of IgG4-Related Disease
date: '2024-11-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39541094/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20241115181608&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: Inebilizumab reduced the risk of flares of IgG4-related
  disease and increased the likelihood of flare-free complete remission at 1 year,
  confirming the role of CD19-targeted B-cell depletion as a potential treatment for
  IgG4-related disease. (Funded by Amgen; MITIGATE ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: Inebilizumab reduced the risk of flares of IgG4-related disease and increased the likelihood of flare-free complete remission at 1 year, confirming the role of CD19-targeted B-cell depletion as a potential treatment for IgG4-related disease. (Funded by Amgen; MITIGATE ClinicalTrials.gov number, ...